Table 4.
Visual field abnormalities in absence of and after one optic neuritis episode
Number of optic neuritis episodes | 0 | 1 | ||||
---|---|---|---|---|---|---|
|
|
|||||
NMO (n = 10 eyes) | MS (n = 30 eyes) | P-value | NMO (n = 33 eyes) | MS (n = 19 eyes) | P-value | |
Foveal threshold | 34 ± 1.8 | 32.5 ± 3.1 | 0.07 | 16.2 ± 15.2 | 27.4 ± 10.4 | 0.01 |
I. Neurologic abnormalities | 0 | 1 (3.3%) | 0.9 | 7 (21.3%) | 3 (15.8%) | 0.9 |
I.1. Vertical step | 0 | 0 | – | 0 | 0 | – |
I.2. Quadrant | 0 | 0 | – | 3 (9%) | 0 | 0.4 |
I.3. Partial hemianopia | 0 | 0 | – | 1 (3%) | 0 | 0.9 |
I.4. Hemianopia | 0 | 0 | – | 1 (3%) | 0 | 0.9 |
I.5. Three quadrant | 0 | 1 (3.3%) | 0.9 | 2 (6%) | 3 (15.8%) | 0.5 |
II.1. Nerve fiber bundle abnormalities | 3 (30%) | 8 (26.7%) | 0.9 | 9 (27.3%) | 4 (21%) | 0.9 |
II.1.a. Temporal wedge | 0 | 0 | – | 0 | 0 | – |
II.1.b. Enlarged blind spot | 0 | 0 | – | 0 | 1 (5.3%) | 0.9 |
II.1.c. Nasal step | 0 | 3 (10%) | 0.7 | 1 (3%) | 0 | 0.9 |
II.1.d. Paracentral | 3 (30%) | 4 (13.3%) | 0.4 | 3 (9%) | 0 | 0.4 |
II.1.e. Partial arcuate | 0 | 0 | – | 0 | 1 (5.3%) | 0.9 |
II.1.f. Arcuate | 0 | 1 (3.3%) | 0.9 | 1 (3%) | 2 (10.5%) | 0.6 |
II.1.g. Altidudinal | 0 | 0 | – | 4 (12.1%) | 0 | 0.3 |
II.2. Diffuse abnormalities | 2 (20%) | 9 (30%) | 0.8 | 2 (6%) | 8 (42.1%) | 0.005 |
II.2.a. Multiple foci | 2 (20%) | 4 (13.3%) | 0.9 | 0 | 2 (10.5%) | 0.2 |
II.2.b. Widespread | 0 | 5 (16.6%) | 0.4 | 2 (6%) | 6 (31.6%) | 0.04 |
II.3. Central abnormalities | 0 | 2 (6.7%) | 0.9 | 0 | 2 (10.5%) | 0.2 |
II.3.a. Centrocecal | 0 | 0 | – | 0 | 1 (5.3%) | 0.9 |
II.3.b. Central | 0 | 2 (6.7%) | 0.9 | 0 | 1 (5.3%) | 0.9 |
II.4.a. Total loss of vision | 0 | 0 | – | 13 (39.4%) | 1 (5.3%) | 0.01 |
Artifactual abnormalities | 0 | 0 | – | 0 | 0 | – |
Normal | 5 (50%) | 10 (33.3%) | 0.5 | 2 (6%) | 1 (5.3%) | 0.9 |
Abbreviations: MS, multiple sclerosis; NMO, neuromyelitis optica.